ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL
Harry Iland(Royal Prince Alfred Hospital), Andrew H. Wei(The Royal Melbourne Hospital), N Weber(George Huntington Institute), Rosemary Harrup(University of Tasmania), Tasman Armytage(Gosford Hospital), Liane Khoo(The University of Sydney), Hayley B. Schultz(University of South Australia), Ashley P. Ng(The Royal Melbourne Hospital), William Stevenson(The University of Sydney), John Reynolds(The Alfred Hospital), Anne-Marie Watson(Liverpool Hospital), Sam Yuen(Calvary Mater Newcastle Hospital), Fiona Kwok(Westmead Hospital), Robin Gasiorowski(The University of Sydney), Paula Marlton(The University of Queensland), Steven Lane(QIMR Berghofer Medical Research Institute), Shaun A Fleming(The Alfred Hospital), Peter Tan(Royal Perth Hospital), Leesa Rowley(Australasian Leukaemia and Lymphoma Group), Robin Filshie(St Vincent's Hospital Melbourne), Alan V. Boddy(University of South Australia)
Cited by 4
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
The genomic landscape of hypodiploid acute lymphoblastic leukemia
|Nature Genetics|2013|737